Risk of malignant progression in Barrett's Esophagus patients: Results from a large population-based study

Journal of the National Cancer Institute

Volumn 103, Issue 13, 2011, Pages 1049-1057

  Bhat, Shivaram ^a   Coleman, Helen G ^a   Yousef, Fouad ^a   Johnston, Brian T ^b   McManus, Damian T ^c   Gavin, Anna T ^d   Murray, Liam J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL VICTORIA HOSPITAL   (United Kingdom)

^c BELFAST CITY HOSPITAL   (United Kingdom)

^d QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BARRETT ESOPHAGUS; CANCER GROWTH; CANCER RISK; CARDIA ADENOCARCINOMA; CARDIA CARCINOMA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS DISEASE; ESOPHAGUS DYSPLASIA; FOLLOW UP; HUMAN; INCIDENCE; INTESTINE METAPLASIA; IRELAND; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; SEX DIFFERENCE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; CARDIA; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; INCIDENCE; INTESTINES; KAPLAN-MEIER ESTIMATE; MALE; METAPLASIA; MIDDLE AGED; NORTHERN IRELAND; PRECANCEROUS CONDITIONS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK FACTORS; STOMACH NEOPLASMS;

EID: 79960249713     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr203     Document Type: Article

References (42)

1. Cook MB, Chow WH, Devesa SS. Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977-2005. Br J Cancer. 2009;101(5):855-859.
2. Steevens J, Botterweck AA, Dirx MJ, van den Brandt PA, Schouten LJ. Trends in incidence of oesophageal and stomach cancer subtypes in Europe. Eur J Gastroenterol Hepatol. 2010;22(6):669-678.
3. Eloubeidi MA, Mason AC, Desmond RA, El-Serag HB. Temporal trends (1973-1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope? Am J Gastroenterol. 2003;98(7):1627-1633. (Pubitemid 36875359)
4. US National Cancer Institute. SEER Stat Fact Sheets: Esophagus; 2010. http://seer.cancer.gov/statfacts/html/esoph.html-survival. Accessed October 5, 2010.
5. Lagergren J. Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk? Gut. 2005;54(suppl 1):i1-i5. (Pubitemid 40293002)
6. British Society of Gastroenterology. Guidelines for the Diagnosis and Management of Barrett's columnar-lined oesophagus; 2010. http://www.bsg.org.uk/ clinical-guidelines/oesophageal/guidelines-for-the-diagnosis-and-management-of- barrett-s-columnar-lined-oesophagus.html. Accessed October 5, 2010.
7. Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol. 2008;103(3):788-797. (Pubitemid 351406009)
8. Somerville M, Pitt M. Surveillance of Barrett's oesophagus: do we yet know whether it is worthwhile? Frontline Gastroenterol. 2010;1(2):88-93.
9. Garside R, Pitt M, Somerville M, Stein K, Price A, Gilbert N. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling. Health Technol Assess. 2006;10(8):1-142. iii-iv.
10. Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol. 1999;94(8):2043-2053. (Pubitemid 29374530)
11. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology. 2000;119(2):333-338. (Pubitemid 30621983)
12. Yousef F, Cardwell C, Cantwell MM, Galway K, Johnston BT, Murray L. The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. Am J Epidemiol. 2008;168(3):237-249. (Pubitemid 352019777)
13. Riddell RH, Odze RD. Definition of Barrett's esophagus: time for a rethink-is intestinal metaplasia dead? Am J Gastroenterol. 2009;104(10):2588- 2594.
14. Murray L, Watson P, Johnston B, Sloan J, Mainie IM, Gavin A. Risk of adenocarcinoma in Barrett's oesophagus: population based study. BMJ. 2003;327(7414):534-535. (Pubitemid 37088499)
15. Marsman WA, Tytgat GN, ten Kate FJ, van Lanschot JJ. Differences and similarities of adenocarcinomas of the esophagus and esophagogastric junction. J Surg Oncol. 2005;92(3):160-168. (Pubitemid 41779298)
16. Chandrasoma P, Wickramasinghe K, Ma Y, DeMeester T. Adenocarcinomas of the distal esophagus and "gastric cardia" are predominantly esophageal carcinomas. Am J Surg Pathol. 2007;31(4):569-575. (Pubitemid 46569041)
17. de Jonge PJ, van Blankenstein M, Looman CW, Casparie MK, Meijer GA, Kuipers EJ. Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study. Gut. 2010;59(8):1030-1036.
18. Jung KW, Talley NJ, Romero Y, et al. Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett's esophagus: a population-based study [published online ahead of print April 12, 2011]. Am J Gastroenterol. 2011.
19. Gopal DV, Lieberman DA, Magaret N, et al. Risk factors for dysplasia in patients with Barrett's esophagus (BE): results from a multicenter consortium. Dig Dis Sci. 2003;48(8):1537-1541. (Pubitemid 36936690)
20. Gatenby PA, Caygill CP, Ramus JR, Charlett A, Watson A. Barrett's columnar-lined oesophagus: demographic and lifestyle associations and adenocarcinoma risk. Dig Dis Sci. 2008;53(5):1175-1185. (Pubitemid 351514632)
21. de Jonge PJ, Steyerberg EW, Kuipers EJ, et al. Risk factors for the development of esophageal adenocarcinoma in Barrett's esophagus. Am J Gastroenterol. 2006;101(7):1421-1429. (Pubitemid 43980612)
22. Avidan B, Sonnenberg A, Schnell TG, Chejfec G, Metz A, Sontag SJ. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma. Am J Gastroenterol. 2002;97(8):1930-1936.
23. Oberg S, Wenner J, Johansson J, Walther B, Willen R. Barrett esophagus: risk factors for progression to dysplasia and adenocarcinoma. Ann Surg. 2005;242(1):49-54. (Pubitemid 40917967)
24. Bani-Hani K, Sue-Ling H, Johnston D, Axon AT, Martin IG. Barrett's oesophagus: results from a 13-year surveillance programme. Eur J Gastroenterol Hepatol. 2000;12(6):649-654. (Pubitemid 30433541)
25. van Soest EM, Dieleman JP, Siersema PD, Sturkenboom MCJM, Kuipers EJ. Increasing incidence of Barrett's oesophagus in the general population. Gut. 2005;54(8):1062-1066. (Pubitemid 41025895)
26. van Blankenstein M, Looman CW, Johnston BJ, Caygill CP. Age and sex distribution of the prevalence of Barrett's esophagus found in a primary referral endoscopy center. Am J Gastroenterol. 2005;100(3):568-576. (Pubitemid 40487554)
27. Spechler SJ, Goyal RK. The columnar-lined esophagus, intestinal metaplasia, and Norman Barrett. Gastroenterology. 1996;110(2):614-621. (Pubitemid 26043897)
28. McGarrity TJ. Barrett's oesophagus: the continuing conundrum. BMJ. 2000;321(7271):1238-1239.
29. Chandrasoma P, Wickramasinghe K, Ma Y, DeMeester T. Is intestinal metaplasia a necessary precursor lesion for adenocarcinomas of the distal esophagus, gastroesophageal junction and gastric cardia? Dis Esophagus. 2007;20(1):36-41. (Pubitemid 46099873)
30. Sharma P, Weston AP, Morales T, Topalovski M, Mayo MS, Sampliner RE. Relative risk of dysplasia for patients with intestinal metaplasia in the distal oesophagus and in the gastric cardia. Gut. 2000;46(1):9-13. (Pubitemid 30307669)
31. Weston AP, Sharma P, Mathur S, et al. Risk stratification of Barrett's esophagus: updated prospective multivariate analysis. Am J Gastroenterol. 2004;99(9):1657-1666. (Pubitemid 39237488)
32. Conio M, Cameron AJ, Romero Y, et al. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut. 2001;48(3):304-309. (Pubitemid 32269555)
33. Gatenby PA, Caygill CP, Ramus JR, Charlett A, Fitzgerald RC, Watson A. Short segment columnar-lined oesophagus: an underestimated cancer risk? A large cohort study of the relationship between Barrett's columnar-lined oesophagus segment length and adenocarcinoma risk. Eur J Gastroenterol Hepatol. 2007;19(11):969-975. (Pubitemid 350287403)
34. Dulai GS, Shekelle PG, Jensen DM, et al. Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett's cohort. Am J Gastroenterol. 2005;100(4):775-783. (Pubitemid 40592365)
35. Skacel M, Petras RE, Gramlich TL, Sigel JE, Richter JE, Goldblum JR. The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression. Am J Gastroenterol. 2000;95(12):3383-3387.
36. Hage M, Siersema PD, van Dekken H, Steyerberg EW, Dees J, Kuipers EJ. Oesophageal cancer incidence and mortality in patients with long-segment Barrett's oesophagus after a mean follow-up of 12.7 years. Scand J Gastroenterol. 2004;39(12):1175-1179. (Pubitemid 39656830)
37. Lim CH, Treanor D, Dixon MF, Axon AT. Low-grade dysplasia in Barrett's esophagus has a high risk of progression. Endoscopy. 2007;39(7):581-587. (Pubitemid 47098993)
38. Wright TA, Gray MR, Morris AI, et al. Cost effectiveness of detecting Barrett's cancer. Gut. 1996;39(4):574-579. (Pubitemid 26376042)
39. Streitz JM Jr., Ellis FH Jr., Tilden RL, Erickson RV. Endoscopic surveillance of Barrett's esophagus: a cost-effectiveness comparison with mammographic surveillance for breast cancer. Am J Gastroenterol. 1998;93(6):911-915. (Pubitemid 29076975)
40. Nilsson J, Skobe V, Johansson J, Willen R, Johnsson F. Screening for oesophageal adenocarcinoma: an evaluation of a surveillance program for columnar metaplasia of the oesophagus. Scand J Gastroenterol. 2000;35(1):10-16. (Pubitemid 30066765)
41. Macdonald CE, Wicks AC, Playford RJ. Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study. BMJ. 2000;321(7271):1252-1255.
42. Northern Ireland Statistics and Research Agency. Migration Statistics; 2010. http://www.nisra.gov.uk/demography/default.asp18.htm. Accessed August 18, 2010.